drugset / Trial / NCT02527564

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

NCT02527564

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. The investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.

Timeline

Start
2015-09
Primary completion
2021-03-01
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Suvorexant Small molecule 20 mg